Filing Flows › Nuvation Bio (NUVB) › Q2 2026
Nuvation Bio (NUVB) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 6, 2026
Nuvation Bio (NUVB) reported revenue of $31.7M for the second quarter 2026 (Q2 2026), +556% from a year earlier and -62% from the quarter before. Operating margin was -161.1%, net loss $62.8M (198.3% of revenue).
Nuvation Bio, Q2 2026: revenue $31.7M (+556% year over year), operating margin -161.1%, net loss $62.8M, operating cash flow −$43.0M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $31.7M | -62% | +556% |
| Operating profit | −$51.0M | -1415% | — |
| Net earnings | −$62.8M | -1264% | — |
| Operating cash flow | −$43.0M | -948% | — |
What changed
Revenue was $31.7M in Q2 2026, up 556% year over year and down 62% from the previous quarter. Product Revenue was the largest line at 73% of revenue. License added $4.9M year over year (up 136%), 18% of the total change.
Operating costs exceeded revenue by $51.0M, an operating margin of -161.1%. The fastest-growing cost line was Research & development (+12%). The quarter ended with a net loss of $62.8M, after a profit of $5.4M the previous quarter.
Operating cash flow was −$43.0M. Non-cash charges added back $536K of depreciation and amortization and $10.5M of share-based compensation. Working capital and other items added $8.9M.
Questions
What was Nuvation Bio's revenue in the second quarter 2026?
Nuvation Bio (NUVB) reported revenue of $31.7M for the second quarter 2026 (Q2 2026), +556% from a year earlier and -62% from the quarter before.
Was Nuvation Bio profitable in the second quarter 2026?
Operating loss was $51.0M (-161.1% of revenue) and net loss $62.8M.
Source: Nuvation Bio 10-Q on SEC EDGAR.